The problem of racemization in drug discovery and tools to predict it

Ballard, Andrew, Narduolo, Stefania, Ahmad, Hiwa O., Cosgrove, David A., Leach, Andrew G. and Buurma, Niklaas J. ORCID: https://orcid.org/0000-0003-0260-5057 2019. The problem of racemization in drug discovery and tools to predict it. Expert Opinion on Drug Discovery 14 (6) , pp. 527-539. 10.1080/17460441.2019.1588881

Preview

PDF - Accepted Post-Print Version Download (394kB) | Preview

Abstract

Introduction: Racemization has long been an ignored risk in drug development, probably because of a lack of convenient access to good tools for its detection and an absence of methods to predict racemization risk. As a result, the potential effects of racemization have been systematically underestimated. Areas covered: Herein, the potential effects of racemization are discussed through a review of drugs for which activity and side effects for both enantiomers are known. Subsequently, drugs known to racemize are discussed and the authors review methods to predict racemization risk. Application of a method quantitatively predicting racemization risk to databases of compounds from the medicinal chemistry literature shows that success in clinical trials is negatively correlated with racemization risk. Expert opinion: It is envisioned that a quantitative method of predicting racemization risk will remove a blind spot from the drug development pipeline. Removal of the blind spot will make drug development more efficient and result in less late-stage attrition of the drug pipeline.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Chemistry Advanced Research Computing @ Cardiff (ARCCA)
Publisher:	Informa Healthcare
ISSN:	1746-0441
Date of First Compliant Deposit:	8 April 2019
Date of Acceptance:	26 February 2019
Last Modified:	01 Dec 2024 16:15
URI:	https://orca.cardiff.ac.uk/id/eprint/121600

Citation Data

Cited 6 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item